Compare SCLX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | ASRT |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.0M | 76.0M |
| IPO Year | N/A | 2004 |
| Metric | SCLX | ASRT |
|---|---|---|
| Price | $8.05 | $11.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 41.4K | 35.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $749.70 | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.18 | $0.51 |
| 52 Week High | $34.27 | $12.95 |
| Indicator | SCLX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 37.66 | 56.76 |
| Support Level | $7.82 | $0.67 |
| Resistance Level | $12.30 | $12.75 |
| Average True Range (ATR) | 0.63 | 0.54 |
| MACD | 0.19 | -0.24 |
| Stochastic Oscillator | 28.25 | 28.03 |
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.